
This issue marks my first year as Editor-in-Chief of the Société Internationale d’Urologie Journal (SIUJ) [...]
This issue marks my first year as Editor-in-Chief of the Société Internationale d’Urologie Journal (SIUJ) [...]
Background/Objectives: Repeat transurethral resection of bladder tumor (TURBT) remains important in selected high-risk non-muscle-invasive bladder cancer (NMIBC) because residual tumor may persist after initial resection, yet some patients may undergo an ultimately tumor-negative procedure. Postoperative urinary molecular testing may provide a noninvasive approach to identify residual disease before repeat TURBT. This review evaluated the diagnostic performance and potential triage value of postoperative urinary nucleic-acid assays for detecting histologically confirmed residual tumor before repeat TURBT in patients with high-risk NMIBC. Methods: PubMed, Scopus, Web of Science, and the Cochrane Library were searched. Eligible studies included adults with high-risk NMIBC undergoing initial TURBT, postoperative urinary nucleic-acid testing before repeat TURBT, and histopathological residual-disease assessment. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies, version 2 (QUADAS-2). Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for diagnostic test accuracy. Findings were synthesized narratively. Results: Of 3231 records, four studies met the eligibility criteria. Performance varied across assays. UroAmp Prognosis achieved 97% sensitivity and 89% negative predictive value (NPV); UroAmp minimal residual disease (MRD) achieved 72% sensitivity, 80% specificity, and 57% NPV. utLIFE achieved 80.7% sensitivity, 96.2% specificity, and 90.1% NPV. The H4 Clustered Histone 6 (H4C6)/Twist Family bHLH Transcription Factor 1 (TWIST1) methylation panel achieved 65.2% sensitivity, 87.5% specificity, and a calculated NPV of 77.8%. OncoUrine achieved an NPV of approximately 82% in the high-risk subgroup. Certainty was very low for UroAmp Prognosis, UroAmp MRD, the H4C6/TWIST1 panel, and utLIFE, and low for OncoUrine in the high-risk subgroup. No included study evaluated omission of repeat TURBT based on a negative molecular result. Conclusions: Postoperative urinary molecular assays remain promising investigational tools, but the available evidence is of low to very low certainty and does not establish that repeat TURBT can safely be omitted after a negative result. Prospective external validation and management-impact studies are required before routine clinical use for this purpose.
Background/Objectives: Large language models (LLMs) such as ChatGPT, Gemini and Claude are increasingly used by patients to research new diagnoses, including testicular cancer. The aim of this study was to evaluate and compare the quality of responses generated by these three platforms to patient-facing frequently asked questions on testicular cancer, including a focused evaluation of fertility and sexual health questions. Methods: Fifteen questions were developed from established patient education resources and refined by senior urology consultant review. Each question was posed to ChatGPT, Gemini and Claude using a standardised patient-perspective prompt. The 45 responses were de-identified, randomised and assessed in a single consensus meeting by a urology panel using the Quality Analysis of Medical Artificial Intelligence (QAMAI) tool. Comparative analysis used the Friedman test with Bonferroni-corrected pairwise Wilcoxon signed-rank testing. Results: All three models produced moderate quality responses, with a mean total QAMAI score of 21.8 for ChatGPT, 22.4 for Claude, and 22.1 for Gemini (Friedman p = 0.246). Clarity differed significantly between models (adjusted p = 0.022), with Claude and Gemini outperforming ChatGPT. In the fertility and sexual health domain, Claude (24.0) and Gemini (23.0) outperformed ChatGPT (19.7). No response from any model spontaneously cited references or directed the reader to external resources. Conclusions: ChatGPT, Gemini and Claude deliver broadly equivalent overall quality on patient-facing testicular cancer questions, with inter-model differences in clarity and in the fertility and sexual health domain. The absence of source citation is a clinically relevant limitation. These tools should be regarded as a supplement to, rather than a substitute for, specialist counselling.